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CHAPTER -1
INTRODUCTION1-9
1 . SOLID DISPERSION SYSTEM AND ITS 
HISTORICALBACKGROUND
Fincher1 reviewed in 1968 the effect of the particle size of drugs on their dissolution 
rates  and  biological  availability  comprehensively.  The  enhancement  of  oral 
bioavailability of poorly water-soluble drugs remains one of the most challenging aspects 
of drug development. Bioavailability can be defined as the rate and extent at which the 
drug is delivered to the systemic circulation from dosage form and reaches the site of 
action to produce the desired effect. Any new drug whose aqueous solubility is less than 
0.01  µg/ml  will  definitely create  a  bioavailability  problem and  thereby affecting  the 
therapeutic  efficiency  of  a  new  drug.  Once  if  we  are  able  to  increase  the  aqueous 
solubility of a drug, the disintegration and dissolution properties can be easily altered, as 
a  result,  an  increase  in  bioavailability  can  be  easily  achieved.  Methods  to  increase 
aqueous solubility of a drug are Salt  formation,  solubilization, particle size reduction, 
complexation, solvent evaporation, solid solution and solvent formation. They have been 
commonly  used  to  increase  dissolution  rate  and  thereby  oral  absorption  and 
bioavailability of such drugs2. There are practical limitations to these techniques. In 1961, 
Sekiguchi and Obi2  developed a practical method whereby many of the limitations with 
the  bioavailability enhancement  of  poorly water-soluble  drugs  just  mentioned can  be 
overcome.  This  method  which  was  later  termed  as  ‘Solid  Dispersion,  involved  the 
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formation of eutectic mixtures of drugs with water-soluble carriers by the melting of their 
physical mixtures.
Poorly water soluble drugs
Tablet/ Capsule
Dosage form
olid particles
Fig. 1: Schematic representation of the bioavailability enhancement of poorly water-
soluble drug by solid dispersion compared with conventional tablet or capsule.
Sekiguchi  and  Obi2   in 1961 suggested that the drug was present in a eutectic 
mixture in a microcrystalline state. Later, Goldberg et al 3    in 1966 demonstrated that the 
entire drug in solid dispersions might not be necessarily present in a microcrystalline 
state; a certain fraction of the drug might be molecularly dispersed in the matrix, thereby 
forming a solid solution. In either case, once the solid dispersion was exposed to aqueous 
media and carrier dissolved, the drug was released as very fine and colloidal particles. 
Because of greatly enhanced surface area obtained in this way, the dissolution rate and 
the bioavailability of poorly water-soluble drugs were expected to be high.
2. CARRIERS USED FOR SOLID DISPERSIONS
2.1. Poly Ethylene Glycols
Poly ethylene glycols are polymers of ethylene oxide  a molecular weight usually 
falling in the range 200 - 300,000. For solid dispersions PEGs with a molecular weight of 
1500 - 20,000 are usually used. As the molecular weight increases, so does the viscosity 
of PEG. Their solubility in water is generally good but decreases with molecular weight. 
A particular advantage of PEGs for the formation solid dispersions is that, they have good 
solubility in many organic solvents.
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2.2. Poly Vinyl Pyrrolidine  (PVP)
 Polymerization  of  Vinyl  Pyrrolidine  leads  to  Poly Vinyl  Pyrrolidine  (PVP)  of 
molecular weight from 2500 - 3000,000. Due to their good solubility in a wide variety of 
organic solvents, they are particularly suitable for solvent method. Similarly to the PEGs, 
the PVPs have good water solubility and can improve the wettability of the dispersed 
compound  in  many  cases.  The  aqueous  solubility  of  PVPs  becomes  poorer  with 
increasing chain length and further much higher viscosity at a given concentration.
E.g. Poly  Vinyl Alcohol, Poly Vinyl Pyrrolidine Acetate co-polymer.
2.3 HYDROXY PROPYL METHYL CELLULOSE (HPMC)
Hydroxy  propyl  methyl  cellulose  (HPMC)  also  known  as  Hypromellose  of 
molecular weight from 10,000 – 1500000 due to their good solubility in water and in 
mixtures  of  organic  solvents  like  Ethan  and  chloroform ,  Mixtures  of  methanol  and 
dichloromethane like PEGS HPMC also have good water solubility and improving the 
waltability of the compounds, they are particularly suitable for solvent method.
3.  CHARACTERIZATION OF SOLID DISPERSIONS
 The different methods that have been used to characterize solid dispersion are; 
 Thermo analytical methods, differential thermo analysis and hot stage 
microscopy.
 Powder X-Ray diffraction.
 Spectroscopic methods, especially IR spectroscopy.
 Microscopic methods including polarization microscopy and scanning 
electron microscopy.
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 Colorimetric analysis of the solution or melting enthalpy for calculation  of 
entropy change.
 Dissolution testing.
3.1. Therrmo Analytical Methods                   
Thermo analytical methods include all that examine a characteristic of the systems 
as a function of temperature. Of this, Differential scanning calorimetry is the most highly 
regarded method. DSC enables the quantitative detection of all process in which energy is 
required  or  produced,  i.e.,  endothermic  and  exothermic  phase  transition.  The  usual 
method of measurement is to heat the reference and two test samples in such a way that 
the temperature of two is kept identical.
If an energy requirement requiring transition occurs in the test samples, extra heat 
is applied to this sample so that its temperature climbs at the same rate as in the reference. 
The additional heat required is recorded and used to quantitate the energy or the phase 
transition.
Exothermic  transitions,  such  as  conversion  of  one  polymorph  to  a  more  stable 
polymorph, can be also detected.  Lack of a melting peak in DSC of solid dispersion 
indicates  that  the  drug  is  present  in  amorphous  than  the  crystalline  form.  Since  the 
method is quantitative in nature, the degree of crystallinity can also be calculated for 
systems  in  which  the  drug  is  partly  amorphous  and  partly  crystalline.  However 
crystallinities of fewer than 2% cannot be generally detected with DSC.
3.2.  X-ray Diffraction
The principle  behind X-RD is  that  when an x-ray beam is  applied to sample, 
interference bands can be detected. The angle at which interference bands can be detected 
18
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can be detected depends on the wavelength applied and the geometry of the sample with 
respect to periodicities in the structure. Crystalline sample is reflected by a characteristic 
finger point region in the diffraction pattern. Owing to the specificity of the finger print, 
crystallinity  in  the  drug can  be  separately identified  from crystallinity  in  the  carrier. 
Therefore,  it  is  possible  with  
X-Ray Diffraction to differentiate between solid dispersions, in which it is partly present 
in  crystalline  form,  regardless  of  whether  the  carrier  is  amorphous  or  crystalline. 
However, crystallinities of under 5-10% cannot generally be detected with X-RD.
3.3.  Infra Red Spectroscopy
Structural changes and lack of a crystal structure can lead to changes in bonding 
between functional groups which can be detected by Infra Red Spectroscopy. Since not 
all  the peaks in the IR spectrum are sensitive to crystalline changes,  it  is possible to 
differentiate between those that are sensitive to changes in crystallinity and those that are 
not.
3.4.  Dissolution Testing
Release rate cannot be used on a stand alone basis to determine whether a solid 
dispersion has been on a basis to determine whether a solid dispersion has been formed or 
not.  However  in  conjunction  with  other  physiochemical  data,  they  provide  strong 
evidence for the formation of a molecularly dispersed or nearly molecularly dispersed 
system.  When  the  goal  of  preparing  a  solid  dispersion  is  to  improve  dissolution 
characteristics of the drug, the results of the release rate experiments are obviously of 
prime  importance  in  assessing  the  success  of  the  approach.  Well  designed  release 
experiments will show whether the solubility of the drug and its dissolution rate can be 
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enhanced,  and also whether the resulting supersaturated solution is  stable or tends  to 
precipitate quickly. Comparison of results with those for pure drug powder and physical 
mixture can help to indicate the dissolution via solubilization and wetting which could be 
affected.
4. DEFINITION AND METHODS OF PREPARATION OF SOLID 
DISPERSIONS
4.1 Definition
The term refers to the dispersion of one or more active ingredients in an inert 
carrier  or  matrix  at  solid  state  prepared  by the  melting  (fusion),  solvent  evaporation 
method and melting solvent method.
4.2.  Methods Of Preparation
Basically there are three methods;
 Melting method.
 Solvent evaporation method.
 Melting-solvent method.
4.2.1. Melting Method
Sekiguchi and Obi3 in 1961 first proposed the melting or fusion method, to 
prepare fast release solid dispersion dosage forms. In this method, the physical mixture of 
drug and water-soluble carrier is heated directly until it is melted. The melted mixture is 
then cooled and solidified in an ice bath under vigorous stirring. The final mass is 
crushed, pulverized and sieved. The dispersion can also be cooled through the process of 
spray congealing using spray-drying equipment. The melted material is sprayed onto cold 
metal surfaces, which forms pellets of the dispersion. This does not require grinding and 
therefore no alteration of the crystal modification of the drug occurs. In addition, the 
dispersion can be cooled at a controlled rate. Fusion system can also be done by a slight 
modification. Here the homogenous melt was poured in the form of a thin layer onto a 
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ferrite plate or stainless steel plate and cooled by flowing air or water onto the opposite 
side of the plate. The solidified masses were stored in the dessicator at ambient 
temperature.
Advantages
 Simplicity and economy.
 Less time consuming.
 This method is also advantageous for compounds, which do not  
undergo significant thermal degradation.
Disadvantages
 The main disadvantage of the melt method includes thermal degradation, 
sublimation, and polymeric transformation, which can affect the physicochemical 
properties of the drug including its rate of dissolution.
 The temperature, at which the dispersion solidifies, affects crystallization rates 
and may alter both the size of the crystals and the hardness of the dispersion. This 
may result in tacky or glossy and unmanageable dispersions, which will require 
storage at elevated temperature, to facilitate hardening.
Examples:
Solid  dispersions  of  Sulphamethoxazole,  Acetaminophen,  Griseofulvin, 
Primidone,  Chloropropamide,  Chloramphenicol,  Tolazamide,  Steroids,  Ketoprofen, 
Nimesulide.
4.2.2.  Solvent Evaporation Method 
This method involves dissolving the drug and carrier in a suitable organic solvent, 
followed by evaporation  of  the solvent  to  form solid  dispersion.  The mass  was then 
stored in a dessicator, pulverized and sieved.
Solvent removal is accomplished by various means. The most common approach 
is the application of reduced pressure at  a fixed temperature to evaporate the organic 
solvent. Temperatures of 125°C for 25 minutes, 115°C for one hour, –5°C and reduced 
pressure followed by drying for 12 hours in vacuum have been used. Spray drying is 
another approach by which solvent removal can be accomplished and it is probably the 
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fastest way of removing solvent. The freeze-drying technique is also employed to prepare 
solid dispersions by removal of aqueous solutions.
Advantages 
The procedure is suitable for drugs that are thermolabile.
 The thermal decomposition of drugs or carriers can be prevented 
because of the low temperature required for the evaporation of the organic 
solvents.
 For aqueous systems, frozen temperature can be used to evaporate the 
solvent, which can enhance the integrity of the drug.
Disadvantages
 Difficulty in complete removal of the solvent.
 Finding a suitable solvent that will dissolve both the drug and carrier is 
very difficult.
 Plasticization of some polymers such as polyvinyl pyrrolidone has 
occurred with the use of some solvents.
 It is important that the rate of evaporation of a solvent is controlled so 
as to control the particle size of the drug, which in turn will affect the rate of 
dissolution of the drug in the solid dispersion.
Examples:
β-Carotene–PVP, Griseofulvin–PVP, Sulfathiazole–PVP, Steroids–PVP, 
Reserpine–deoxycholic acid.
4.2.3.  Melting-Solvent Method
The  drug  is  first  dissolved  in  a  suitable  liquid  solvent  and  solution  is  then 
incorporated directly into a  melt  of PEG obtained below 70°C without  removing the 
liquid solvent. It was shown that 5 -10%w/w of liquid-components would be incorporated 
into PEG 4000 without significant loss of its solid property.
Advantages
 Possess the advantage of both melting and solvent methods.
Disadvantages
 Limited to drugs having therapeutic index below 50 mg.
 Selected solvents or dissolved solution may not be miscible with melt 
of PEG.
Examples:
Solid dispersion of  Clofibrate, Methyl Salicylate, Benzyl Benzoate.
5. FEATURES OF SOLID DISPERSION
 Unified presentation of solid dispersion technology for drugs.
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 Includes recent developments in theory and practice.
 An aid in new drug formulation and improvement of existing drugs.
 Techniques for improved dissolution rate, sustained release, altered solid-
state properties and improved solubility and stability.
6.  CLASSIFICATION AND FAST RELEASE MECHANISMS
6.1. Simple Eutectic Mixtures
The simple eutectic mixture is usually prepared from the rapid solidification of the 
fused liquid of two components, which show solid solubility. When the preparation is 
dissolved in aqueous medium, the carrier will dissolve rapidly, releasing very fine 
crystals of drug, which offers large surface area, thereby improvement in dissolution is 
effected. Thermodynamically, such a system is regarded as an intimately blended 
physical mixture of its two crystalline components.
6.2. Solid Solutions
A solid solution is made-up of a solute dissolved in a solid solvent. It is often 
called a mixed crystal because the two components crystallize together in a homogenous 
one-phase system. A solid solution achieves faster dissolution rate than eutectic mixture 
because, the particle size of the drug in the solid solution is reduced to a minimum state 
i.e. molecular size.
Solid solution can be classified according to the extent of miscibility between the 
two components or the crystalline structure of the solid solution. Based on this, they can 
be divided into four groups: continuous (or isomorphous, unlimited, complete) solid 
solutions, discontinuous (or limited, restricted, partial, incomplete) solid solutions, 
substantial solid solutions and interstitial solid solutions.  
6.2.1. Continuous Solid Solutions
In this system, the two components are miscible or solid state in all proportions. 
The bonding strength between two components is stronger than that between the 
molecules of each component.
6.2.2.  Discontinuous solid solution
There is a limited solubility of a solute in a solid solvent in this group of solid 
solutions.
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6.2.3 Substitutional crystalline solid solution
In this, the solute molecules substitute for the solvent molecules in the crystal  
lattice of the solid solvent. It can form a continuous solid solution.
6.2.4. Interstitial Crystalline Solid Solution
The solute (guest) molecule occupies the interstitial space of the solvent (host) in  
the lattice; it usually forms only a discontinuous (limited) solid solution.
6.3. Glass Solutions
A Glass solution is a homogeneous, glassy system in which a solute dissolves in a 
glassy solvent. It is another potential modification of dosage forms in increasing drug 
dissolution and absorption. The familiar term “glass,” however can be used to describe 
either a pure chemical or a mixture of chemicals in a glossy or vitreous state.
6.4. Amorphous Preparations
The amorphous form is the highest energy form of a pure drug. It should under 
almost  all  conditions,  produce  faster  dissolution  and  high  absorption  rates  than  the 
crystalline  form.  In  amorphous  solid  solution,  the  solute  molecules  are  dispersed 
molecularly but irregularly within the amorphous solvent. Novobiocine has been reported 
to have a ten-fold higher solubility than its crystalline form.
6.5. Complex Formulations
The availability of a drug depends on the intrinsic absorption rate of the complex. 
The  water-soluble  polymers  have  been  considered  as  ideal  carriers  for  the  solid 
dispersion of poorly soluble drugs. 
Advantages Of Solid Dispersions
 Solid dispersion of drugs in solid state is helpful in stabilizing unstable 
drugs. Many of the advantages claimed for SD are derived from their rapid 
dissolution rates. The increased rate of nitrazepam from the citric acid dispersion 
produces increase in the rate and extent of absorption.
 The PEGs may protect certain drugs example: cardiac glycosides against the 
decomposition by saliva and allow buccal absorption.
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 Various fast release solid dispersions can be prepared by solid dispersion 
technique. For example: fast release solid dispersions of Lorazepam can be 
prepared by using urea, PEG 6000 or Mannitol as carriers.
 Solid dispersions may be a thermodynamically more active form of drug and 
directly influence the diffusion and release rate.
 An increased diffusion of steroid from the ointment was obtained, example: solid 
dispersion of prednisolone urea dispersion.
 Solid dispersion technology can be used to solidify liquid drugs, example: 
clofibrate and benzyl benzoate.
Disadvantages Of Solid Dispersions
 Tackiness and decommission during preparation and formulation.
 The oral administration of solid dispersions without concomitant 
reduction in dose may result in higher incidence of adverse effects.
 Ex: ulceration of Indomethacin–PEG 6000 dispersion.
 The physical and chemical stability of drug and vehicle.
 Reproducibility of its physicochemical properties.
 The scale up of manufacturing process.
 Its formulation into dosage forms.
 Difficulty in pulverization.
 Drug carrier incompatibility.
 Poor flow and mixing properties.
 Sifting of the dispersions, which are usually soft and tacky.
The surface modification technique can significantly improve the dissolution of 
hydrophobic drug, by the adsorption of very small amounts of urea at the drug particle 
surface. Techniques have been commonly used to improve dissolution and bioavailability 
of poorly water-soluble drugs, which includes micronization, the use of surfactants, and 
the formation of solid dispersions.
Chiou and Riegelmann4 in 1971 outlined six types of drug-carrier interactions in 
solid-state dispersions. Simple eutectic mixtures, solid solutions, glass solutions, glass 
suspensions, amorphous precipitates in a crystalline carrier and compound or complex 
formation. Other factors such as increased wettability, solubilization of the drug by the 
carrier at the diffusion layer and the reduction or absence of aggregation and 
agglomeration may also contribute to increased dissolution.  
Fig 2:  Classification And Fast Release Mechanisms
FAST RELEASE MECHANISMS
SOLID EUTECTIC MIXTURES
COMPLEX FORMATIONS
SOLID SOLUTIONS
GLASS SOLUTIONS
AMORPHOUS PREPARATIID SOLUTION 
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DISCONTINUOUS SOLID SOLUTIOUBSTANTIAL SOLID SOL
INTEL STable 1 : Solid Dispersions Of Therapeutic Agents
Drug Carrier Method
Type of solid 
Dispersion
Effect of  
Dissolution 
Rate
Triamterene
Β-
cyclodextrin
S, K Not Studied Increased
Flurbiprofen PVP S Not Studied Increased
Caffeine Nicotinamide M Peritechc Increased
Chloramphenicol Urea M
Solid 
Solution
Increased
Clofibrate PEG 6000 M, S Not Studied Increased
Corticosteroids Sugars M Not Studied Increased
Diazepam PEG 4000 M
Eutectic with 
solid 
Solution
Not Studied
Griseofulvin Succinic acid M
Solid 
Solution
Increased
PVP S Not Studied Increased
PVP-30
Spray 
Embedding
Solid 
Solution
Increased
PEG -4000 M, S Not Studied Increased
PEG -6000 M, S Not Studied Increased
PEG-2000 M, S Not Studied Increased
Anhycitric 
acid
M
Glass 
suspension
Increased
Indomethacin PEG 6000 M Not Studied Increased
Methyl salicylate PEG 6000 M,S Not Studied Increased
Paracetamol Urea M
Solid 
solution
Increased
Mannitol M Eutectic Increased
Primidone Citric acid M
Glass 
solution
Increased
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Reserpine PVP S Not Studied Increased
Cholanic acid S Not Studied Increased
Deoxychoilic 
acid
S Not Studied Increased
Sulfathiazole Urea M
Simple 
eutectic
Not Studied
Tolubutamide PEG-4000 S Not Studied Increased
PEG-6000 S Not Studied Increased
PEG 
4000+6000
M, S Not Studied Increased
PEG-2000 M, S Monoacetic Not Studied
PVP S Not Studied Increased
Polyoxyl 40 
stearate
M, S Not Studied Increased
PEG-8000 M, S Not Studied Increased
PVP S Not Studied Increased
PEG-6000 S Not Studied Increased
PEG-4000 M Not Studied Increased
Allopurinol PVP S Not Studied Increased
Benzybenzoate PEG 6000 M, S Not Studied Increased
*M-Melting  Method,  S-Solvent  Method,  MS-  Melting  Solvent  Method,  K-Kneading 
Method.    
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SCHEME OF WORK
The main perspective of the present study aims at overcoming these problems with solid 
dispersion  technology by using carriers  like  HPMC and peg-4000 in  a  view to  develop fast 
release formulation of glimepiride and hence improve its dissolution characteristic. Glimepiride is 
an  effective  anti-diabetic,  which  is  practically  insoluble  in  water,  hence  dissolution  is  rate 
limiting.
 The research work envisaged was,
 Literature survey on solid dispersion, method and carriers for solid dispersion.
 Preparation, characterisation and evaluation of solid dispersion of Glimepiride 
with HPMC, and peg-4000.
 Formulation studies on solid dispersion of Glimepiride.
1. AIM
 To prepare  solid  dispersions of  glimepiride using HPMC and  peg-4000 as  the  inert  
carriers.
 To assay the solid dispersions.
 To evaluate the solid dispersions by in-vitro  dissolution studies in phosphate buffer pH 
7.4. The in-vitro release profiles of prepared solid dispersions were compared with pure drug.
 The samples were also evaluated by using various instrumental techniques.
2.  EXPERIMENTAL DESIGN
 Preparation of glimepiride-peg4000 and glimepiride  -  HPMC  solid  dispersions 
by solvent evaporation method and fusion method.
 Assay of solid dispersions.
 Release studies on solid dispersions in phosphate buffer (pH 7.4).
3. CHARACTERISATION OF SAMPLES BY DIFFERENT METHODS
 XRD- Analysis.
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 DSC-Analysis.
 IR spectroscopic analysis.
 To study the effect of concentration and type of carrier on the release  of  Glimepiride 
from its solid dispersions.
4. FORMULATION STUDIES ON SELECTED SOLID DISPERSION
Release studies on selected solid dispersion with pure drug.
Fig 3:  Plan of Work
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Plan of work
Glimepiride
Method validation by 
Standard graph of glimepiride
Preformulation studies
Preparation HPMC, Peg-4000Polymer used
Drug:Carrier
      1;1
      1;2
      1;3
      1;4
   
Glimepiride-HPMC    SD 
Glimepiride-Peg-4000  SD Dispersion
Development Of Dissolution System Of Glimepiride
Evaluation
DSCCXRDIR
Comparative Study
Comparison Of In- Vitro Release Profile
CHAPTER - 2
DRUG PROFILE10,13,14
GLIMEPIRIDE, a new generation sulphonyl  urea  [Endocrine  Journal,  2007] has several 
benefits: rapid and complete absorption after oral administration, a lower dose, 
long duration action, and possible insulin sensitizing effect. Glimepiride is an oral 
blood glucose lowering drug of sulfonyl urea class.
Chemical Name
Glimepiride  (1–[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl] 
phenyl]  sulfonyl]-3-(trans-4-methylcyclohexyl) urea.
The CAS registry number is 93479-97-1.
Molecular formula: C24H34N4O5S
Molecular Weight: 490.62
Structural formula:
Figure 5: Structure of Glimepiride
Physical properties: Glimepiride is a white to yellowish white crystalline odorless 
powder.
Solubility:  Glimepiride is insoluble in water,  acid,  base, borate and phosphate 
buffers  but  partially  soluble  in  methanol,  ethanol,  acetone,  and  completely 
soluble in DMF[www.aventis.us.com].
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Chemical properties: Methanolic solution of Glimepiride gives UV absorption at 
229nm and aqueous solution of Glimepiride gives maximum absorption between 
229 and 236nm [Indian Journal of Pharmaceutical Sciences].
Log P value: 2.5
C Log P value: 3.96 [www.tsrlinc.com] 
BCS: Class 2 drug (low solubility high permeability) 
Available strength: 1mg, 2mg, and 4mg
Mechanism of Action
The primary mechanism of Glimepiride in lowering blood glucose appears to be 
dependent on stimulating the release of insulin from functioning pancreatic beta 
cells.
In addition extra pancreatic effect may also play a role in the activity of sulfonyl  
urea  such  as  Glimepiride.  This  is  supported  by  both  clinical  and  pre-clinical 
studies  demonstrating  the  Glimepiride  administration  can  lead  to  increased 
sensitivity of peripheral tissues to insulin.
31
31
Pharmacokinetics
Absorption:  After  oral  administration,  Glimepiride  is  completely  (100%) 
absorbed from the GI tract. Studies with single oral doses in normal subjects and 
with multiple oral doses in patients with Type2 has shown significant absorption 
of  Glimepiride  with  1  hour  after  administration  and  peak  drug  levels  at  2  to 
3hours.
Distribution:  After  intravenous (IV)  dosing  in  normal  subjects,  the  volume of 
distribution (Vd) was 8.8L (113ml/kg), and the total body clearance (Cl) was 47.8 
ml/min. Protein binding was greater than 99.5%.
Metabolism: Glimepiride  is  completely  metabolized  by  oxidative 
biotransformation after either an IV or oral dose. The major metabolites are the 
cyclohexyl  hydroxyl  methyl  derivative  (M1)  and  the  carboxyl  derivative  (M2). 
Cytochrome P450 2C9 has been shown to be involved in the biotransformation of 
Glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic 
enzymes. M1, but not M2, possesses about 1/3 of the pharmacological activity as 
compared to its parent in an animal model.
Excretion: When  14C-Glimepiride was given orally,  approximately 60% of  the 
total radioactivity was recovered in the urine in 7 days and M1 (predominant) and 
M2 accounted for 80 – 90% of that recovered in the urine. Approximately 40% of 
that recovered in feces. No parent drug was recovered from urine or feces. 
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Pharmacokinetic Parameters
Table 2: Pharmacokinetic Parameters
Parameter Single Dose
Cmax (ng/ml)
1 mg 103± 34 (12)
2 mg 177 ± 44 (12)
4 mg 308 ± 69 (12)
8 mg 551 ± 152 (12)
Tmax (h) 1.4 ± 0.8 (48)
Cl/f(ml/min) 52.1 ± 16.0 (48)
Vd/f(l) 21.8 ± 13.9 (48)
T1/2(h) 1.3 ± 4.1 (48)
CL/f=Total body clearance after oral dosing
Vd/f=Volume of distribution calculated after oral dosing
Adverse reactions
GASTRO INTESTINAL REACTIONS
Vomiting, gastro intestinal pain and diarrhoea have been reported.
DERMATOLOGIC REACTIONS
Allergic skin reactions, e.g. Pruritus, Erythema, Urticaria occurs.
HEAMATOLOGIC REACTIONS
Leukopenia,  Agranulocytosis,  Thrombocytopenia,  Hemolytic  Anemia,  Aplastic 
Anemia, and Pancytopenia have been reported.
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Indications and Usage  
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood 
glucose  in  patient  with  Type  2  diabetes  mellitus.  Hypoglycemia  cannot  be 
controlled by diet and exercise alone. Glimepiride may be used concomitantly 
with  Metformin  when  diet,  exercise,  Glimepiride  or  Metformin  alone  do  not 
adequate glycemic control. 
Dosage and Administration [Package insert of Amaryl tablets 1, 2 and 4 mg.]
Usual  starting  dose  of  Glimepiride  initial  therapy is  1mg  to  2mg once  daily, 
administered with breakfast or first main meal.
Patient who may be more sensitive to Hypoglycemic drugs should be started at 
1mg once daily, and should be titrated carefully.
The maximum starting dose of Glimepiride should not be more than 2mg. The 
usual maintenance dose is 1 to 4mg once daily. The maximum recommended 
dose is 8mg once daily.
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CHAPTER - 3
POLY ETHYLENE GLYCOL PROFILE15-24
1. NONPROPRIETARY NAMES
BP: Macrogols,  JP: Macrogol  400,  Macrogol  1500,  Macrogol  
4000,  Macrogol  6000,  Macrogol  20000,  PhEur:   Macrogola, 
USPNF: Polyethylene glycol
2. SYNONYMS
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxyethylene glycol.
3. CHEMICAL NAME
α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) 
4. FUNCTIONAL CATEGORY
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant.
5. APPLICATIONS IN  PHARMACEUTICAL TECHNOLOGY
Polyetylene glycols (PEGs) are widely used in a variety of pharmaceutical formulations 
including  parenteral,  topical,  ophthalmic,  oral,  and  rectal  preparations.  It  has  been  used  in 
controlled-release systems.
Polyethylene glycols are water-soluble and are easily removed from the skin by washing, 
making them useful  as ointment  bases.2 Aqueous polyethylene glycol  solutions can be used 
either  as  suspending  agents  or  to  adjust  the  viscosity  and  consistency  of  other  suspending 
vehicles.  When  used  in  conjunction  with  other  emulsifiers,  polyethylene  glycols  can  act  as 
stabilizers.
Liquid polyethylene glycols are used as water-miscible solvents for the contents of soft  
gelatin capsules. In concentrations up to approximately 30% v/v, PEG 300 and PEG 400 have 
been used  as the vehicle for parenteral dosage forms.Polyethylene glycols can also be used to  
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enhance the aqueous solubility or dissolution characteristics of  poorly soluble compounds by 
making solid dispersions with an appropriate polyethylene glycol.
In film coatings, solid grades of polyethylene glycol can be used alone for the film-coating 
of  tablets.  Solid  grades are  also  widely  used  as  plasticizers  in  conjunction  with  film-forming 
polymers.The presence of polyethylene glycols in film coats, especially of liquid grades, tends to 
increase their water permeability and may reduce protection against low pH in enteric-coating 
films.
6. PHARMACOPEIAL SPECIFICATIONS
6.1. Typical Properties
Density  : 1.11–1.14 g/cm3 at  25°C for  liquid  PEGs;  
15–1.21 g/cm3 at 25°C for solid PEGs.
Flash point  : 238°C for PEG 4000;
Freezing point  : 4–8°C for PEG 4000
Melting point  : 50–58°C for PEG 4000.
Moisture content  : Liquid polyethylene glycols are very hygroscopic, 
hygroscopicity  decreases  with  increasing 
molecular weight. Solid grades.
7. SOLUBILITY 
Soluble in water, liquid PEG are soluble in  acetone, alcohols, benzene, 
glycerin,  and  glycols.  Solid  polyethylene  glycols  are  soluble  in  acetone, 
dichloromethane,  ethanol  (95%),  and  methanol;  they  are  slightly  soluble  in 
aliphatic hydrocarbons and ether, but insoluble in  fats, fixed oils, and mineral oil.
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8. SURFACE TENSION
Approximately 44 mN/m (44 dynes/cm) for liquid polyethylene glycols;  approximately  
55 mN/m (55 dynes/cm) for 10% w/v aqueous solution of solid polyethylene glycol.
9. STABILITY AND STORAGE CONDITIONS
Polyethylene glycols are chemically stable in air and in solution, although grades with a 
molecular weight less than 2000 are hygroscopic. Polyethylene glycols do not support microbial 
growth, and they do not become rancid.
Polyethylene glycols  should  be stored in  well-closed containers  in  a  cool,  dry  place. 
Stainless steel, aluminum, glass, or lined steel containers are preferred for the storage of liquid 
grades.
10.   INCOMPATIBILITIES
All grades can exhibit some oxidizing activity owing to the presence of peroxide impurities 
and secondary products formed by autoxidation. Liquid and solid polyethylene glycol grades may 
be  incompatible  with  some  coloring  agents.The  antibacterial  activity  of  certain  antibiotics  is 
reduced in polyethylene glycol bases. The preservative efficacy of  the parabens may also be 
impaired owing to binding with polyethylene glycols.
11.  HANDLING PRECAUTIONS
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Eye protection is recommended.
12.  REGULATORY STATUS
Included in the FDA Inactive Ingredients Guide (dental preparations; IM and IV injections; 
ophthalmic preparations; oral capsules, solutions, syrups, and tablets; rectal, topical, and vaginal 
preparations). Included in nonparenteral medicines licensed in the UK. Included in  the Canadian 
List of Acceptable Non-medicinal Ingredients.
HYPROMELLOSE (HPMC)
Nonproprietary Names 
BP: Hypromellose 
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JP: Hydroxypropylmethylcellulose 
PhEur: Hypromellosum
USP: Hypromellose
Synonyms 
Benecel  MHPC;  hydroxypropyl  methyl  ether;  E464;  hydroxypropyl 
methylcellulose;  HPMC;  Methocel;  methylcellulose  propylene  glycol  ether; 
merthyl  hydroxypropylcellulose;  Metolose  ;  Pharmacoat  ;  Spectracel  6  ; 
Spectracel 15; Tylopur.
Chemical Name and CAS registry number 
Cellulose, 2-hydroxypropyl-methyl ether [9004-65-3]
Empirical formula molecular weight 
The PhEur 2002 describes hypromellose as a partly O-methylated and O-
(2-hydroxypropylated)  cellulose.  It  is  available  in  several  grades  that  vary  in  
viscosity and extent of substitution. Grades may be distinguished by appending a 
number indicative of the apparent viscosity,  in mPa s, of  a 2% w/w aqueous 
solution at 20°C. Hypromellose defined in the USP 25 specifies the substitution 
type  by  appending  a  four-digit  number  to  the  nonproprietary  name:  e.g.,  
hypromellose  1828.  The  first  two  digits  refer  to  the  approximate  percentage 
content  of  the  methoxy  group  (OCH3).  The  second  two  digits  refer  to  the 
approximate percentage content of the methoxy group (OCH3). The second two 
digits refer to the approximate percentage content of the hydroxypropoxy group 
(OCH2CH  (OH)  CH3),  calculated  on  a  dried  basis.  Molecular  weight  is 
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approximately  10  000-1  500  000.  The  Jp  2001  includes  three  separate 
monographs  for  hypromellose:  hydroxypropylmethylcellulose  2208,  2906,  and 
2910, respectively. 
Functional category 
Coating  agent;  film-former;  rate  –  controlling  polymer  for  sustained 
release; stabilizing agent; suspending agent; tablet binder; viscosity – increasing 
agent. 
Applications in pharmaceutical formulation or technology 
Hypromellose  is  widely  used  in  oral  and  topical  pharmaceutions, 
Particularly  ophthalmic  preparations.  Compared  with  methylcellulose, 
hypromellose produces solutions of greater clarity, with fewer undispersed fibers 
present,  and  is  therefore  preferred  in  formulations  for  ophthalmic  use. 
Hypromellose at  concentrations between 0.45-1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions. 
Hypromellose  is  also  used  as  an  emulsifier,  suspending  agent,  and 
stabilizing agent  in  topical  gels  and ointments.  As a protective  colloid,  it  can 
prevent droplets and particles from coalescing or agglomerating, thus inhibiting 
the formation of sediments.
In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is 
also widely used in cosmetics and food products.
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Description
Hypromellose is an odorless and tasteless, white or creamy white fibrous 
or granular powder.
Pharmacopeial specifications 
Typical Properties
Acidity / alkalinity : pH = 5.5 – 8.0 for a 1% w/w aqueous solution
Ash : 1.5-3.0% depending upon the grade
Autoignition temperature: 360°C   
Density (tapped) : 0.557 g/cm3
Density (tapped) : 1.326 g/cm3  
Melting point : browns at 190-200°C; chars at 225-230°C.
Glass transition temperature is 170-180°C.
Moisture  content:  hypromellose  absorbs  moisture  from the  atmosphere,  the 
amount of water absorbed depending and relative humidity of the surrounding air. 
Solubility: soluble in cold water, forming a viscous colloidal solution; practically 
insoluble  in  chloroform,  ethanol  (95%),  and  ether,  but  soluble  in  mixtures  of 
ethanol and dichloromethane, mixtures of methanol and dichloromethane, and 
mixtures of water  and alcohol.  Certain  grades of  hypromellose are soluble in 
aqueous acetone solutions, mixtures of dichloromethane and propan-2-ol,  and 
other organic solvents. 
Specific gravity: 1.26
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Viscosity (dynamic): Wide ranges of viscosity types are commercially available. 
Aqueous solutions are most  commonly prepared,  although hypromellose may 
also be dissolved in aqueous alcohols such as ethanol and propan-2-ol provided 
the alcohol content is less than 50% w/w. Dichloromethane and ethanol mixtures 
may also be used to prepare viscous hypromellose solutions. Solutions prepared 
using organic solvents tend to be more viscous; increasing concentration also 
produces more viscous solutions; 
Methocel grade Nominal Viscosity (MPa s)
K 100LVP 100 80-120
K4M 4000 3000-5600
K15MP 15000 12000-2100
K100MP 100 000 80 000-120 000
To prepare an aqueous solution, it is recommended that hypromellose is 
dispersed and thoroughly hydrated in about 20-30% of the required amount of 
water. The water should be vigorously stirred and heated to 80-90°C, then the 
remaining hypromellose added. Cold water should then be added to produce the 
required volume.
When  a  water  –  miscible  organic  solvent  such  as  ethanol,  glycol,  or 
mixtures of ethanol and dichloromethane is used, the hypromellose should first  
be dispersed into the organic solvent, at a ratio of 5-8 parts of solvent to part of 
hypromellose. Cold water is then added to produce the required volume. 
Stability and storage conditions
Hypromellose powder is a stable material, although it is hygroscopic after 
drying.
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Solutions  are  stable  at  pH  3-11.  Increasing  temperature  reduces  the 
viscosity  of  solutions.  Hypromellose  undergoes  a  reversible  sol-gel 
transformation upon heating and cooling, respectively. The gel point is 80-90°C, 
depending upon the grade and concentration of material.
Aqueous  solutions  are  comparatively  enzyme-resistant,  providing  good 
viscosity stability during long-term storage.However, aqueous solutions are liable 
to microbial spoilage and should be preserved with an antimicrobial preservative: 
when  hypromellose is  used as   a  viscosity  –  increasing  agent  in  ophthalmic 
solutions, benzalkonium chloride is commonly used as the preservative. Aqueous 
solutions may also be sterilized by autoclaving; the coagulated polymer must be 
redispersed on cooling by shaking.
Hypromellose powder should be stored in a well-closed container,  in a 
cool, dry place.
Incompatibilities
Hypromellose  is  incompatible  with  some  oxidizing  agents.  Since  it  is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates.
safety 
Hypromellose  is  widely  used  as  an  excipient  in  oral  and  topical 
pharmaceutical formulations. It is also used extensively in cosmetics and food 
products. 
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Hypromellose is generally regarded as a nontoxic and nonirritant material, 
although excessive oral consumption may have a laxative effect. The WHO has 
not  specified  an  acceptable  daily  intake  fro  hypromellose  since  the  levels 
consumed were not considered to represent a hazard to health. 
LD 50 (mouse, IP): 5 g/kg (16)
LD 50 (rat, IP): 5.2 g/kg
Handling precautions 
Observe  normal  precautions  appropriate  to  the  circumstances  and 
quantity of material handled. Hypromellose dust may be irritant to the eyes and 
eye protection is recommended. Excessive dust generation should be avoided to 
minimize the risks of explosion. Hypromellose is combustible63. 
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CHAPTER - 4
LITERATURE REVIEW 34-60
Sethia  and  Squillante   (2004)58 were  prepared  solid  dispersion  of 
carbamazepine in PVP K30 by conventional solvent evaporation and supercritical 
methods. They have suggested that the best intrinsic dissolution rate (IDR) was 
obtained  for super critically processed CBZ/PVP K30 that was four-fold higher 
than pure CBZ and the supercritical-based process produced augmented with 
amphiphilic carriers. 
Eun-Jung et al.,  (2006)59 has studied the dissolution rates of felodipine 
musing PVP and HPMC carriers by solvent wetting method. It could be shown 
that the dissolution rates of felodipine in PVP and HPMC solid dispersion were 
much  faster  than  those  for  they  corresponding  physical  mixtures.  However 
dissolution profiles were found to depend on the carrier used; the dissolution rate 
of  felodipine  increased  slowly  for  solid  dispersions  prepared  using  HPMC, 
whereas  rapid  initial  dissolution  rate  were  observed  for  solid  dispersions 
prepared  using  PVP or  poloxamer.  Increases  in  dissolution  rate  were  partly 
dependent on the ratios of felodipine to carrier. No significant changes in crystal 
form were  observed by X-ray diffraction or thermal analysis, and no significant 
changes in dissolution rate were observed when sorbitol and mannitol were used 
as carriers. 
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Naveen  et  al.,  (2007)60 have  studied  enhancement  of  dissolution  and 
mathematical modeling of drug release of a poorly water-soluble drug (rofecoxib) 
using  water-soluble  carriers  viz.  polyethylene  glycols  (PEG  4000  and  6000), 
polyglycolized fatty acid ester (Gelucire 44/14), polyvinylpyrollidone K25 (PVP), 
poloxamers  (Lutrol  F127  and  F68),  polyols  (mannitol,  Sorbitol),  organic  acid 
(citric  acid  )  and  hydrotropes.  All  the  solid  dispersion  showed  dissolution 
improvement vis-à-vis pure drug to varying degress, with citric acid, PVP and 
poloxamers  as  the  most  promising  carriers.  Solid-state  characterization 
techniques  revealed  that  distinct  loss  of  drug  crystallinity  in  the  formulation,  
ostensibly accounting for enhancement in dissolution rate. 
Qureshi  et  al.,  (1998)34 have  been  studied  the  variability  in  drug  dissolution 
testing of prednisone tablets and a marketed glibenclamide tablet product. The 
experiments  were  conducted  using  paddle  and  basket  methods  at  50 
(calibrators) and 75 (glibenclamide) rpm. The media employed were deaerated 
by equilibrating at 37ºC for 24 h and by the USP recommended method. The 
95% CI  values  for  percent  drug  release  for  the  USP calibrator  tablets  were 
similar  to  the reported tolerances for  the USP  Acceptance Ranges;  however, 
individual results from 15 of 28 laboratories suggest that the apparatus would not 
comply  with  the  USP  Apparatus  Suitability  Criteria.  For  FDA  prednisone 
calibrator tablets, percent drug release using equilibrated medium was different 
(P50.003) than by the USP recommended method. For the glibenclamide tablet 
results, a CV of 14–37% was observed, depending upon the sampling time and 
the type of apparatus employed. The results indicate that failure to meet the USP 
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Dissolution Apparatus Suitability Test  may not truly mean that the apparatus is 
‘out  of  compliance’.  Due to  the high variability in dissolution testing,  in many 
cases  the  impact  of  formulation  or  manufacturing  changes  on  drug  release 
characteristics may not be observed, in particular with multi-point profiles.
Aceves et al., (1999)35 have been studied on solid dispersion and physical 
mixtures  were  prepared  and  characterized  by  X-ray,  infrared  spectroscopy, 
electronic microscopy and dissolution rate studies. The characterization with X-
ray showed a transition  from the  crystalline  to  the  amorphous phase.  A new 
phase near 50% furosemide concentration with both type of carrier was present 
from  infrared  spectroscopy  strong  interaction  between  amine  and  carbonyl 
groups  from  both  the  furosemide  and  the  polymer  were  found.  Electronic 
microscopy analysis  showed that  the furosemide changed its  crystalline habit 
from  needle  to  a  new  spherical  phase,  with  diameter  near  to  1µm.  Solid 
dispersion  were  prepared  in  order  to  modify  the  system  characteristics.  The 
furosemide  dissolution  rate  was  determine  in  order  to  follow  the  behaviour 
changed of the system. Scanning electron microscopy showed the present of 
microspheres within the polymer matrix,  and the channels formed due to the 
frosemide dissolution inside the Eudragit, this fact modified the release pattern of 
the frusemide system.  
Lin et al.,  (1999)36 have been reported surface modified human serum 
albumin (HSA) nanoparticles with a size of approximately 150 nm in diameter 
were  prepared  from  a  PEG-HSA  conjugate,  methoxy-polyethylene  glycol 
modified human serum albumin (HSA-mPEG) using a coacervation method and 
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crosslinked  with  glutaraldehyde.  The  z-potential  of  the  surface  modified 
nanoparticles was significantly lower than that of unmodified HSA nanoparticles. 
The existence of  a  hydrated steric  barrier  surrounding the nanoparticles  was 
confirmed by electrolyte and pH induced flocculation tests. The surface modified 
nanoparticles  showed  a  reduced  plasma  protein  adsorption  on  the  particle 
surface compared with unmodified particles.
Dash  et  al., (2002)37 reported  ethylcellulose  microspheres  containing 
tolnaftate were prepared by the emulsion- solvent evaporation technique. An X-
ray  powder  diffractometric  method  was  developed  to  quantify  the  content  of 
crystalline  tolnaftate  in  these  microspheres  X-ray  lines  of  tolnaftate  with  d-
spacings of 5.5 and 4.1Aº were chosen for the quantitative analyses. Physical 
mixture  containing  various  weight  fraction  of  tolnaftate  and  blank  (empty) 
microspheres were prepared and lithium fluoride (20%w/w) was added as the 
internal standard. The 5.5 and 4.3 lines of tolnaftate and the 2.3Aº line of lithium 
fluirde  where  used  for  the  quantitative  analysis.  A plot  of  the  intensity  ratio 
(intensity of the 5.5Aº line of tolnaftate / intensity of 2.3 Aº line of lithium fluoride) 
as a function of weight percent of tolnaftate in the mixture, resulted in a straight  
line. The crystal line content of tolnaftate in the tolnaftate-loaded microspheres 
was determined using the standard curve. A second independent determination 
of the content of tolnaftate was possible from the intensities of the 4.3 Aº line. 
The  enthalpy  of  fusion  of  tolnaftate,  determined  by  differential  scanning 
calorimetry(DSC),  was  also  used  as  a  measure  of  the  crystalline  content  of  
tolnaftate in the microspheres. The X-ray and DSC methods measure the content 
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of crystalline tolnaftate in the microspheres in the room temperature( ˜ 25ºC) and 
at  the  melting  point  of  tolnaftate  (111ºC),  respectively.  The  total  content  of 
tolnaftate microspheres was determined by HPLC. The DSC and X-ray results 
indicated that a substantial fraction of the incorporated tolnaftate was desoved in 
the ethylcellulose matrix.
Fude  cui et  al.,  (2003)38 reported  to  improve  the  bioavailability  of 
nitrendipine  microspheres,  a  sustained-release  microspheres  having  solid 
dispersion structure were prepared in one step. Two types of polymer, i.e. solid 
dispersing  and  sustained-release  polymers  were  employed  to  prepare  the 
microspheres  by  the  spherical  crystallization  technique,  i.e.  quasi-emulsion 
solvent  diffusion method.  The factors of  effect  on micromeritic properties and 
release  profiles  of  the  resultant  microspheres  were  investigated.  And  the 
bioavailability of  nitrendipine microspheres was evaluated in six healthy dogs. 
The results showed that the particle size of microspheres was determined mainly 
by the agitation speed. The dissolution rate of nitrendipine from microspheres 
was enhanced significantly with increasing the amount of dispersing agents, and 
sustained by adding retarding agents. The release rate of microspheres could be 
controlled as desired by adjusting the combination ratio of dispersing agents to 
retarding  agents.  The  results  of  X-ray  diffraction  and  differential  scanning 
calorimetry  analysis  indicated  that  the  crystalline  form  of  nitrendipine  was 
disordered, suggesting that nitrendipine was highly dispersed in microspheres, 
so as amorphous state. The release profiles and content of the microspheres 
stored at a temperature of 40ºC and a relative humidity of 75% were unchanged 
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during  3  months  of  accelerating  condition  of  storage.  And  the  relative 
bioavailability  of  the  sustained-release  microspheres  compared  with  the 
Baypress_ tablets and the conventional tablets was 107.78% and 309.82%. In 
conclusion,  the sustained-release microspheres with  solid dispersion structure 
improved the bioavailability of the water insoluble drug and prolonged the  Tmax  
value.
Gupta  et  al.,  (2004)39 studied  the solubility enhancement and enthalpy 
relaxation studies with respect to PVP concentration helped in a better prediction 
of role of carrier and optimization of concentration in the use of solid dispersions 
or amorphous systems. The drug release mechanism is drug-controlled rather 
than carrier-controlled.
Elaine Merisko-Liversidge  et al., (2004)40 have studied water insoluble 
Zn-insulin  can be formulated  as  a  stable,  biologically  active  nanometer-sized 
peptide particle dispersion using wet  media milling technology,  capsules differ 
from gelatin, which will require modification to dissolution testing methodology for  
certain drugs. However,  for  the class II  BCS drug ibuprofen,  the two capsule 
types were not statistically different when comparing AUC and Cmax values, which 
suggests that the in vitro differences have reduced in vivo relevance.
Ewart et al., (2004)41 have been studied the in vitro preformance of HPMC 
capsules differ from gelatin, which will require modificationto dissolution testing 
methodology for certain drugs. However, for the class II BSC drug ibuprofen, the 
two capsule type were not satistically different when comparing AUC and Cmax 
values, which suggest that the in vitro differences have reduced in vivo relevance
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Verma et al., (2004)42 have been worked on extended release formulation 
of  glipizide based on osmotic  technology was developed and evaluated.  The 
effect of different formulation variables, namely, level of solubility modifier in the 
core, membrane weight gain, and level of pore former in the membrane, were 
studied. Drug release was found to be affected by the level of solubility modifier 
in  the  core  formulation.  Glipizide  release  was  inversely  proportional  to  the 
membrane weight but directly related to the initial level of pore former (PVP) in 
the membrane. Burst strength of the exhausted shells increased with the weight 
gain of  the membrane.  On the other  hand,  burst  strength decreased with  an 
increase in the level  of pore former in the membrane. Drug release from the 
developed  formulations  was  independent  of  pH  and  agitational  intensity,  but 
dependent on the osmotic pressure of the release media. Results of SEM studies 
showed the formation of pores in the membrane from where the drug release 
occurred. The numbers of pores were directly proportional to the initial level of 
pore former in the membrane. The manufacturing procedure was found to be 
reproducible and formulations were stable after 3 months of accelerated stability 
studies.
Rogers et  al., (2004)43 studied  on  controlled  precipitation  by  scalable 
technology  that can be used to enhance the dissolution of poorly water-soluble 
pharmaceutical compounds.
Ould-Ouali et  al.,  (2004)44 reported  the  polyester  diblock  copolymer 
mmePEG750-CAP/  TMC  forms  spontaneously  stable  micelles  in  aqueous 
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medium and increases the solubility of lipophilic drugs. They are very promising 
vehicles for the oral delivery of poorly water-soluble drugs.
Feng-Qian Li et al., (2004)45 have studied the solid dispersion of silymarin 
were  prepared  by  the  fusion  method  with  the  intention  of  improving  the 
dissolution properties of silymarin. Polyethylene glycol (PEG 6000) was used as 
the inert hydrophilic matrix. The dissolution studies of the solid dispersions were 
performed in vitro. And the results obtained showed that the dissolution rate of 
silymarin was considerably improved when formulated in solid dispersion with 
PEG 6000 as compared to  original  drug ,  and the increased dissolution rate 
might be favorable for further oral absorption.
Verma et al., (2005)46  have been studied for the development of extended 
release formulations  of  glipizide,  techniques of  thermal  and isothermal  stress 
testing  (IST)  were  used to  assess the  compatibility  of  glipizide  with  selected 
excipients. Initially, differential scanning calorimeter (DSC) was used to evaluate 
the compatibility. IR spectrum of drug–excipient mixture was also compared with 
that  of  pure  drug  and  excipient.  Compatibility  of  excipients  defined  in  the 
prototype  formula  was  tested  using  IST.  Based  on  the  DSC  results  alone, 
magnesium stearate, meglumine, TRIS buffer, and lactose, were found to exhibit 
interaction with glipizide. Stressed binary mixtures (stored at 50ºC for 3 weeks) of 
glipizide  and  meglumine  showed  yellow  coloration  indicating  potential 
incompatibility. Based on the results of DSC, IR, and/or HPLC, excipients defined 
in  the  prototype  formula  were  found  to  be  compatible  with  glipizide.  The 
optimized formulation developed using the compatible excipients were found to 
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be stable after 3 months of accelerated stability  studies (40ºC and 75% RH). 
Overall,  compatibility  of  excipients  with  glipizide  was  successfully  evaluated 
using  the  combination  of  thermal  and  IST  methods  and  the  formulations 
developed using the compatible excipients was found to be stable.
Patel et al., (2005)47 have been studied on formulation and evaluation of 
in  vitro and  in  vivo performances of  mucoadhesive  microspheres of  glipizide. 
Glipizide  microspheres  containing  chitosan  were  prepared  by  simple 
emulsification phase separation technique using glutaraldehyde as a crosslinking 
agent.  Results of  preliminary trials  indicate that volume of crosslinking agent, 
time  for  crosslinking,polymer-to-drug  ratio,and  speed  of  rotation  affected 
characteristics of  microspheres.Microspheres were discrete, spherical,and free 
flowing. The microspheres exhibited good mucoadhesive property in the in vitro 
wash-off test and also showed a high percentage drug entrapment efficiency.A 3 
2  full  factorial  design  was  employed  to  study  the  effect  of  independent 
variables,polymer  to  drug  ratio  (X1  ),and  stirring  speed  (X2  )on  dependent 
variables,  percentage  mucoadhesion,drug  entrapment  efficiency,  and  swelling 
index. The best batch exhibited a high drug entrapment efficiency of 75%and a 
swelling index of 1.42; percentage mucoadhesion after 1 hour was 78%.The drug 
release was also sustained for more than 12 hours.The polymer to drug ratio had 
a  more  significant  effect  on  the  dependent  variables.In  vivo testing  of  the 
mucoadhesive  microspheres  to  albino  Wistar  rats  demonstrated  significant 
hypoglycemic effect of glipizide. 
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Shahla Jamzad et al., (2006)48 reported that the  depending on the dose 
size  and  solubility  characteristics  of  low  solubility  drugs,  a  meaningful  and 
discriminatory power of dissolution rate testing can be demonstrated. Saturation 
solubility  of  fenofibrate  and  glipizide  in  different  media  were  determined. 
Solubility of fenofibrate increased directly with SLS concentration. For a 54-mg 
fenofibrate tablet, SLS at 0.025 M level is required for a discriminative dissolution 
test, while for 160-mg tablet, dissolution condition and levels of SLS should be 
optimized; higher con-centrations may be effective (ie, 0.052 M, ~1.5%). A pH 6.8 
phosphate  buffer  medium is  appropriate  for  glipizide  10-mg tablet  dissolution 
study, when formulation ingredients include excipients with surface activity (eg, 
HPMC).
Aftab  modi et  al.,  (2006)49 Iinvestigated  the  enhancement  of  the 
dissolution profile of valdecoxib using solid dispersion with PVP. The article also 
describes the preparation of fast –dissolving tablet of valdecoxib by using a high 
amount of superdisintegrant. A phase solubility method was used to evaluate the 
effect  of  various  water  –soluble  polymer  on  aqeous  solubility  of  valdecoxib. 
Polyvinyl  pyrrolidone  (PVP  K-30)  was  selected  and  solid  dispersion  were 
prepared by the method of kneading. Dissolution studies using the USPpaddle 
method  were  performed  for  solid  dispersion  of  valdecoxib.  Infrared  (IR) 
spectroscopy,  differential  scanning  calorimetry  (DSC),  and  X-ray 
diffractometry(XRD) were performed to indentify the physicochemical interaction 
between drug and carrier, hence its effect on dissolution. Tablets were formulated 
containing solid dispersion products and compared with commercial products. IR 
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spectroscopy,XRD  and  DSC  showed  no  change  in  the  crystal  structure  of 
valdecoxib.  Dissolution of valdecoxib improved significantly in solid dispersion 
products(<85% in 5 miniutes). Tablets containing solid dispersion exhibited better 
dissolution perofile than commercial tablets. Thus, the solid dispersion technique 
can be successfully used for improvement of dissolution of valdecoxib.
Prego et  al.,  (2006)50 have been studied on chitosan nanocapsules to 
enhance and prolong the oral absorption of peptides. They designed a new type 
of  nanocapsule,  using  chitosan chemically modified  with  poly(ethylene glycol) 
(PEG) (0.5% and 1% pegylation degree) and to investigate the cosequences of 
this  modification  on  the  in  vitro and  in  vivo behaviour  of  the  nanocapsules. 
Chitosan PEG nanocapsules and the control PEG-coated nanoemulsions were 
obtained by the solvent displacement technique. Their size was in the range of 
160-250nm. Their zeta potential was greatly affected by the nature of the coating, 
being positive for chitosan-PEG nanocapsules and negative in the case of PEG-
coated  nanoemulsions.  The  presence  of  PEG,  whether  alone  of  grafted  to 
chitosan, improved the stability of the nanocapusles in the gastrointestinal fluids. 
Using the caco-2 model cell line it was observed that the pegylation of chitosan 
reduced the cytotoxicity of the nanocapsules. In addition, these nanocapsules did 
not cause a significant change in the transepithelial resistance of the monolayer.  
Finally, the results of the  in vivo studies showed the capacity of chitosan-PEG 
nanocapsules  to  enhance  and  prolong  the  intestinal  absorption  of  salmon 
calcitonin. Additionally, they indicated that the peglyation degree affected the in 
vivo performance of the nanocapsules. Therefore, by modulating the pegylation 
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degree of chitosan, it was possible to obtain nanocapsules with a good stablility, 
a low cytotoxicity and with absorption enhancing properties.
Fude Cui et al., (2006)51  studied on biodegradation nanoparticles loaded 
with insulin-phospholipid complex by a novel reverse micelle-solvent evaporation 
method, in which soyabean phosphatidylcholine(SPC) was employed to improve 
the  liposlubility  of  insulin,and  biodegradable  polymers  as  carrier  materials  to 
control drug release. Solubilization study,IR and X-ray diffraction analysis were 
employed to prove the complex formation. The effects of key parameters such as 
polymer/SPC weight ratio, organic phase and polymer type on the properties of 
the nanoparticles were investigated. Spherical particles of 200nm mean diameter 
and narrow size distribution were obtained under optimal conditions. The drug 
entrapment efficiency upto 90%. The in vitro drug release was characterized by 
an  initial  burst  and  subsequent  delayed  release  in  both  pH  6.8  and  pH  1.2 
dissolution  mediums.  The  specific  modality  of  drug  relase,  i.e.,  free  of  SPC-
combined,  was  investigated  in  the  aid  of  ultracentrifugation  and  ultrafiltration 
methods. The influence of polymer type on the drug release was also discussed. 
The pharmacological effects on the nanopartilces made of PLGA 50/50 (Av. Mw 
9500) were further evaluated to confirm their potential suitability for oral delivery. 
Intra gastric administrations of the 20 IU/kg nanopartilces reduced fasting plasma 
glucose levels to 57.4% within the first 8 h of administration and this continued 
for 12 h. PK / PD analysis indicated that 7.7% of oral bioavailability relative to 
subcutaneous injection was obtained.
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Siriporn  Okonogi et  al.,  (2006)52 investigated  solid  dispersion  system 
consisting of drug, carrier, and surfactant. Solid dispersions of a water insoluble 
ofloxacin (OFX) with polyethylene glycol  (PEG) of different molecular weights, 
namely binary solid dispersion systems, were prepared at drug to carrier not less 
than 5:5. Polysorbate 80, a nonionic surfactant, was incorporated into the binary 
solid  dispersion  systems  as  the  third  component  to  obtain  the  ternary  solid 
dispersion  systems.  The  powder  x-ray  diffraction  and  differential  scanning 
calorimetric studies indicated that crystalline OFX existed in the solid dispersions 
with high drug loading. However, a decreased crystallinity of the solid dispersions 
obtained revealed that a portion of OFX was in an amorphous state. The results 
indicated  a  remarkably  improved  dissolution  of  drug  from  the  ternary  solid 
dispersion systems when compared with  the binary solid  dispersion systems. 
This was because of polysorbate 80, which improved wettability and solubilized 
the non molecularly dispersed or crystalline fraction of OFX..
Kalaiselvan et  al.,  (2006)53 have  been stidied  the  mechanism of  drug 
release from solid dispersion of Albendazole, giving emphasis to particle size of 
the drug in solid dispersion. Solid dispersion were prepared using three different 
carriers,  mixing  ratios  and  methods  in  an  attempt  to  improve  solubility  and 
dissolution rate of  Albendazole.  The mechanism of  enhanced dissolution was 
investigated by a novel  dissolution  technique as  an adjunct  to  face solubility 
study,  wettability  test,  differential  scanning  calorimetry,  X-ray  diffractometry, 
infrared  spectroscopy  and  scanning  electron  microscopy.  The  solubility  of 
Albendazole  was  greater  with  Albendazole-poloxmer407  system,  while 
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polyethylene glycol dispersion showed predominant wettablilty. Physical mixture 
showed  enhanced  dissolution  compared  with  the  pure  drug,  due  to  improve 
wetting  and  solubilization  of  drug  in  the  diffusion  layer  offering  carrier-reach 
microenvironment. Preparation of solid dispersion  further improve the dissolution 
compared  the  physical  mixture,  owing  to  increased  surface  area  for  mass 
transfer, thermodynamically enhance dissolution of a higher energy amorphous 
form from the carrier, in addition to improved wetting and solubilization. All carrier 
showed comparitable degree of drug particle size reduction, whereas mixing ratio 
and method of preparation substantially effect the particle size. Intermolecular 
association of drug  with the carrier lead to inhibition of drug recrystallization.
Panchagnula et al.,  (2007)54 studied the  in vitro evaluation of modified 
release formulations, containing and compared their performance with a novel 
matrix-based multiparticulate systems. The results indicate that eventhough the 
marketed formualations are found to comply to the definition of modified release 
formulations and predicted the therapeutic blood level for a prolonged period of  
time, the fluctuations were expected to be found uncontrol except in the osmotic 
system and the matrix-based multiparticulate system. Thus, it was concluded that 
novel  matrix-based  multiparticulate  system were  found  to  be  superior  to  any 
other marketed formulations with respect to the therapeutic advantage as well as 
manufacture fesiblility.
Srinivas  Mutalik  et  al.,  (2007)55 Celecoxib  spherical  agglomerates  were 
prepared with polyvinyl pyrrolidone(PVP) using acetone, water and chloroform as 
solvent,  non-solvent  and  bridging  liquid,  respectively.  The  agglomerates  were 
characterized by differential scanning calorimetry(DSC), X-ray diffraction(XRD), IR 
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spectroscopic  study  and  scanning  electron  microscopy(SEM).  The  IR 
spectroscopy and DSC results indicated the absence of any interactions between 
drug  and  additives.  The  XRD  studies  showed  a  decrease  in  crystallinity  in 
agglomerates.  The  crystal  exhibited  significantly  improved  micromeritics 
properties compared to pure drugs. The loading efficency(% or mg drug per 100 
mg crystal) was in the range of 93.9± 2.3 and 97.3± 1.3%(n=3) with all formulations. 
The  aqueous  solubility  and  dissolution  rate  of  the  drug  from  crystal  was 
significantly (p<0.05) increased (nearly two times). The solubility and in  vitro drug 
release rates increased with an increase in PVP concentration(from 2.5 to 10%). 
The SEM studies showed that the crystal  posses a good spherical  shape with 
smooth and regular surface. 
Prajapati et al., (2007)56 have been studied the enhancement of  dissolution 
properties of carbamazepine by solid dispersion technique. Physical mixtures and 
solid dispersions of carbamazepine were prepared to enhance its water solubility. 
Physical  mixtures  and  solid  dispersions  of  carbamazepime  were  prepared  by 
using  polyvinyl  pyrrolidone  K-30,  polyethylene  glycol  4000  and  polyethylene 
glycol 6000 as water-soluble carrier at various proportion (1:0.1, 1:0.2, 1:0.4, 1:0.6, 
1:0.8,  by  weight)  by employing solvent  evaporation  method.  The  drug  release 
profile  was  studied  according  to  USP XXXIII  monograph  in  1% sodium lauryl 
sulphate solution.  It  was found that  the amount  of  the carrier,  i.e.,  the higher 
amount  of  carrier  used,  the  higher  dissolution  rate  was  obtained  except  for 
polyvinyl  pyrrolidone  K-30  and  PEG  4000  solid  dispersions.  Amoung  carrier 
studied solid dispersion of carbamazepine : PVP K 30 at 1:0.2(drug:carrier ratio) 
gave highest dissolution. The increase in dissolution rate of drug may be due to 
increase wettability, hydrophilic nature of the carrier and also possiblility due to 
reduction in drug crystallinity.
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CHAPTER - 5
ANALYTICAL METHOD
1. THE  METHODOLOGY  USED  IN  THE  PRESENT  STUDY  IS  UV  
SPECTROPHOTOMETRY
1.1. Potassium Dihydrogen Phosphate, 0.2 M Solution 
Take  accurately  weighed  27.318  gm of  Potassium dihydrogen  Phosphate  and 
dissolved in 1000 ml of distilled water, this will give 0.2 M KH2PO4.
1.2. Sodium hydroxide 0.2 N solution  
Take accurately weighed 8 gm of sodium hydroxide and dissolved in 1000 ml of 
distilled water, this will give 0.2 N NaOH solution.
1.3. Preparation of pH 7.4 phosphate buffer 
Place 50 ml of the Potassium dihydrogen Phosphate solution in a 200 ml standard 
volumetric flask and add 39.1 ml of sodium hydroxide solution to this flask and make up 
the volume with distilled water.
2. PROCEDURE FOR STANDARD GRAPHS PREPARATION
2.1. Standard graphs preparation with phosphate buffer pH 7.4
Accurately weigh 100 mg of glimepiride  and transfer to a 100 ml volumetric 
flask  and  add  minimum  quantity  of  Methanol  to  solubilise  the  drug,  and  then  add 
phosphate buffer pH 7.4 to make up the volume up to 100ml, this gives the stock solution 
I (1000 µg/ml).
From  stock  solution  I,  pipette  out  10  ml  and  make  up  the  volume  to  
100 ml with phosphate buffer pH 7.4, this gives the stock solution II (100 µg/ml).
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From the stock solution II, pipette out 0.5, 1.0, 1.5, 2.0, and 2.5 ml into 5 separate 
10 ml volumetric flasks respectively, then make up the volume up to the mark to give 5,  
10, 15, 20 and 25 µg/ml concentration solutions and the phosphate buffer pH 7.4 was 
taken as blank.
The absorbance was measured at 236nm and the graph was plotted against concentration 
(µg/ml) Vs absorbance. 
Table No. 3 : Standard Graph of Glimepiride wih phosphate buffer pH7.4.
Sl. No. Concentration (µ g/ml) Absorbance at 236nm
1 0 0.0000
2 5 0.1249
3 10 0.2490
4 15 0.3730
5 20 0.4920
6 25 0.6202
Fig :  4  Standard graph of glimepride with phosphate buffer pH 7.4
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EXPERIMENTAL SECTION 
1. MATERIALS AND EQUIPMENT USED
Table 4 :   Materials Used
Materials Source
Glimepride
Aristo  pharmaceuticals  pvt.  Ltd. 
mumbai
Franco-indian pharmaceutical pvt.Lltd.
mumbai
Methanol Qualigens fine chemicals.,Mumbai.
SLS Qualigens fine  chemicals, Mumbai.
HPMC Qualigens fine  chemicals, Mumbai.
PEG-4000 Sisco Research laboratory .,Mumbai.
Chloroform Qualigens fine chemicals.,Mumbai.
Ethyl acetate Qualigens fine chemicals.,Mumbai.
Potassium dihydrogen phosphate Qualigens fine chemicals.,Mumbai.
Sodium hydroxiode Qualigens fine chemicals.,Mumbai.
Precoated TLC plates Merck Pvt.Ltd., Germany.
Aluminium Foil sheet Hindalco industries Ltd.
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Table  5 : Equipment used
Equipment Model/Company
UV-visible spectrophotometer JASCO V-530 & SHIMADZU 1700.
FT-IR Spectrophotometer JASCO FT-IR 410.
Digital Balance SHIMADZU type-BL 220H.
Balance Dhona-200D and XP-3000.
Camera Gel Dock.
Powder X-ray DIffractometer Anchor.
DSC Meffler – Toledo.
SEM Hitachi S-450
Dissolution apparatus Electrolab TDT- 08L.
Vaccum pump Gelman Sciences.
Magnetic Stirrer Remi Stirrer Equipment.
pH tester-1 Eutech & Oakton.
Hydraulic pellet press Type-WT.
Temperature controller Electrolab-ETC-11L.
Printer Wipro-LQ1050+DX.
TLC viewer CAMAG.
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2. PREPARATION AND EVALUATION OF GLIMEPIRIDE SOLID 
DISPERSION
Solid  dispersion  technology  can  be  used  to  improve  the  in  vitro  and  in  vivo  
dissolution properties of poorly water soluble drugs.  Glimepiride is  poorly soluble in 
water.  The  dissolution  rate  from  solid  dispersion  was  affected  by  the  carrier 
concentration.  HPMC  and  peg-4000   were  used  as  carriers  in  the  preparation  of 
glimepiride solid dispersion.
2.1. procedure for preparation of glimepiride solid dispersion by fusion  method
Polymer  has been taken in china disc and kept in a mantle a constant temperature 
programming  for  melting.   After  reaching  melting  point  than  add  the   drug  with 
continuous stirring with a glass rod. After  taking it out from the mantle,kept  immediate 
for cooling in a ice bath, after  cooling take it out  and kept  in dessicator   with high 
vaccum more than 350Hg.
2.2. Procedure for preparation of glimepiride  solid dispersion by solvent 
evaporation method
In solvent evaporation method solvent [methanol] is used and four different drug: 
carrier ratios were used(1;1, 1;2, 1;3, 1;4 )to prepare solid dispersion of glimepiride.
The resulting mixture was stirred for 1h and evaporated at a temperature of 55° 
until dry. The dried mass was pulverized and sieved through the mesh no. 100
2.3. Procedure for preparation of glimepiride  physical mixture
Drug : carrier ratio of  1:1 was used to prepare physical mixture(500mg of drug 
and 500 mg of carrier).  The drug and the carrier  were mixed thoroughly in a 
63
63
mortar. This was done by geometric dilution technique to ensure homogeneous 
distribution. 
Table  6 : Drug:carrier content ratios and respective amount taken
S. No Drug  : carrier ratio Drug content (mg) Carrier content (mg)
1 1;1 500 500
2 1;2 333 666
3 1;3 250 750
4 1;4 200 800
3. CHARACTERIZATION OF GLIMEPIRIDE SOLID DISPERSION
3.1. IR spectral analysis
Fourier transform infrared (FTIR) spectra of the samples were obtained in the 
range of 2000 to 400 cm-1 using a Jasco – FT-IR 410 PC spectrophotometer (Jasco,), by 
the KBr disc method. The IR spectra  has been observed in the wave rance of 900, 1032, 
1159, 1528, 1650 and 1690. The IR spectra has been given in the following fig 5 to 13 . 
3.2. Powdered x-ray diffraction studies
 The  powdered  X-ray  diffraction  patterns  where  recorded  using  Anchor 
diffractometer, with Cu as anode material, operated at a voltage of 30kv and a current of 
15mA. The samples were analysed in the 2 theta angle range of 5°-50° and the process 
parameters were set as follows- sampling width of 0.010°(2θ) at  scanning speed of 1°/ 
min and scan mode set is continuous. The X-ray diffraction spectras are given in fig 
64
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3.3. Differential scanning calorimetry
The DSC measurements were performed using Meffler – Toledo DSC 821e DSC 
module  controlled  by  STARe  software  (Meffler-Toledo  GmbH,  Switzerland).  All 
accurately weighed samples (1 mg of glipizide or its equivalents) were placed in sealed 
aluminium pans, before heating under  dry nitrogen flow (20 ml/min) at a scanning rate 
of 10oC min-1, over the temperature range of 25oC – 300oC. An empty aluminium pan was 
used as reference. The thermograms are showing below fig 
Fig.  5 : I R  Spectra of PEG4000
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Fig.  6 : I R  Spectra of HPMC
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Fig.  7 : I R  Spectra of Glimepiride
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Fig.  8 : I R  Spectra of Glimepiride and PEG4000 ( by solvent evaporation method)
Fig.  9 : I R  Spectra of Glimepiride and HPMC ( by solvent evaporation method)
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Fig.  10 : I R  Spectra of Glimepiride and PEG4000 ( Fusion method)
Fig.  11 : I R  Spectra of Glimepiride and HPMC ( Fusion method)
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Fig.  12 : I R  Spectra of Glimepiride and PEG4000 ( Physical mixture) 
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Fig.  13 : I R  Spectra of Glimepiride and HPMC ( Physical mixture)
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Fig 14 : X-ray diffraction studies of glimepiride solid dispersion with PEG 4000
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Fig 15 : X-ray diffraction studies of glimepiride solid dispersion with HPMC
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Fig 16 : X-ray diffraction studies of glimepiride 
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Fig 16 : X-ray diffraction studies of glimepiride 
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Fig 17 : DSC Studies of PEG4000
Fig 18 : DSC Studies of HPMC
Fig 19 : DSC Studies of Glimepiride
4. EVALUATION OF SOLID DISPERSION
4.1. Drug content uniformity
The  glimepiride  solid  dispersions,  which  were  prepared  and  tested  for 
drug,  content  uniformity.  From  each  batch  of  solid  dispersions  (prepared  in 
different ratios) equivalent to 10 mg of glimepiride were taken and analyzed for 
drug content uniformity.
4.2. Estimation of solid dispersion by uv spectrophotometry
Accurately weighed amount of solid dispersion  were dissolved in 0.2M, 
pH 7.4 buffer solution in 10 ml of volumetric flask which was previously cleaned 
and dry. This solution after suitable dilution was measured at 236 nm in a JASCO 
V-530 UV/Vis spectrophotometer. The results are shown in Table No. 
Table 7 : Drug Content Uniformity
Solid 
Dispersion
Drug : 
Carrier
Amount 
of SD 
taken 
(mg)
Expected 
Amount 
of drug 
in SD 
(mg)
% of 
Glimepiride
(by solvent 
evaporation) 
estimated by 
UV 
spectrophoto
meter
% of 
Glimepiride 
(by fusion ) 
estimated by 
UV 
spectrophot
ometer
Glimepiride – 
PEG4000
1 : 1
1 : 2
1 : 3
1 : 4 
10
10
10
10
5
3.3
2.5
2
98.4
99.8
97.2
99.2
97.21
96.21
96.12
92.21
Glimepiride - 
HPMC
1 : 1
1 : 2
1 : 3
1 : 4
10
10
10
10
5
3.3
2.5
2
99.4
98.21
97.21
99
98.91
99.81
94.28
94.21
DISSOLUTION RATE STUDIES OF DIFFERENT SOLID DISPERSIONS OF 
GLIMEPIRIDEDE 
The dissolution studies are most important part of the evaluation of solid 
dispersions,  where  the  dissolution  of  pure  drug  and  solid  dispersions  were 
carried out, by using dissolution apparatus, which is shown in figure
Dissolution rate studies of various solid dispersions were carried out in 
0.2M,  pH  7.4  phosphate  buffer  using  USP  XXIV  dissolution  rate  apparatus 
(Electro Lab).
Dissolution method
900  ml.  of  0.2  M,  pH  7.4  phosphate  buffer  was  used  as  dissolution 
medium. SD equivalent  to  40 mg of  Glimepiride was taken in  a  hard gelatin 
capsule. The paddle type stirrer was adjusted to 70 rpm and the temperature was 
maintained at 37°±5°C. 5 ml aliquot dissolution media was withdrawn at different 
time  intervals  and  volume  withdrawn  was  replaced  with  fresh  quantity  of 
dissolution media.
The  samples  were  analyzed  for  Glimepiride  after  suitable  dilution  by 
measuring absorbance at 236nm using Jasco V-530, UV/Vis. spectrophotometer. 
0.2M,  pH  7.4  phosphate  buffer  was  used  as  blank  solution.  The  dissolution 
experiment  work  was  conducted  in  triplicate.  The  percentage  of  Glimepiride 
dissolved at various time intervals was calculated and plotted against time. 
Table 8 :    Dissolution of glimepiride solid dispersion (solvent evaporation) by PEG 
4000 at different drug : carrier ratios
MEDIUM : 0.2M Phosphate Buffer pH 7.4
TEMPERATURE :       37ºC±5ºC
RPM : 70
Time 
(Min)
Percentage Glimepiride dissolved
Pure 
Drug 
(4 mg)
Physical 
Mixture
(1:1)
1:1 1:2 1:3 1:4
0 0 0 0 0 0 0
5 1.36 1.9 3.2 5.2 3.0 2.4
10 2.03 2.8 5.1 7.5 4.3 4.0
15 4.54 6.1 10.1 15.1 12.3 11.1
30 5.87 9.4 27.9 28.3 26.1 25.2
45 7.13 10.8 38.7 40.5 30.6 30.3
60 10.81 12.3 50.3 52.4 42.7 39.1
90 16.19 18.9 57.3 63.7 50.4 48.2
120 19.99 27.3 65.4 76.57 61.2 58.7
Fig. No 20

Table 9 :    Dissolution of glimepiride solid dispersion (solvent evaporation) 
by HPMC at different drug : carrier ratios
MEDIUM : 0.2M Phosphate Buffer pH 7.4
EMPERATURE :       37ºC±5ºC
RPM : 70
Time 
(Min)
Percentage Glimepiride dissolved
Pure 
Drug 
(4 mg)
Physical 
Mixture
(1:1)
1:1 1:2 1:3 1:4
0 0 0 0 0 0 0
5 1.36 2.3 2.0 2.1 1.8 1.5
10 2.03 3.8 3.0 3.20 2.7 2.0
15 4.54 5.3 10.1 10.0 9.8 9.0
30 5.87 6.8 19.2 19.4 17.6 15.6
45 7.13 8.6 28.8 30.2 26.4 22.1
60 10.81 10.1 30.4 39.5 38.1 36.4
90 16.19 15.2 46.3 52.4 49.2 40.8
120 19.99 21.0 61.9 69.3 56.2 54.3
Fig. 21
Table 10 :    Dissolution of glimepiride solid dispersion (Fusion method) by 
PEG 4000 at different drug : carrier ratios
MEDIUM : 0.2M Phosphate Buffer pH 7.4
EMPERATURE :       37ºC±5ºC
RPM : 70
Time 
(Min)
Percentage Glimepiride dissolved
Pure 
Drug 
(4 mg)
Physical 
Mixture
(1:1)
1:1 1:2 1:3 1:4
0 0 0 0 0 0 0
5 1.36 1.9 2.9 3.8 2.0 2.3
10 2.03 2.8 4.0 5.4 3.7 3.2
15 4.54 6.1 9.2 11.0 8.6 7.7
30 5.87 9.4 21.9 23.7 10.7 10.6
45 7.13 10.8 33.3 35.6 28.3 26.4
60 10.81 12.3 41.2 47.8 40.1 30.2
90 16.19 18.9 50.1 55.2 49.5 40.5
120 19.99 27.3 62.6 71.4 58.1 55.4
Fig. : 22
Table 11:    Dissolution of glimepiride solid dispersion (Fusion method) by 
HPMC at different drug : carrier ratios
MEDIUM : 0.2M Phosphate Buffer pH 7.4
EMPERATURE :       37ºC±5ºC
RPM : 70
Time 
(Min)
Percentage Glimepiride dissolved
Pure 
Drug 
(4 mg)
Physical 
Mixture
(1:1)
1:1 1:2 1:3 1:4
0 0 0 0 0 0 0
5 1.36 2.3 1.7 1.8 1.5 1.3
10 2.03 3.8 2.5 2.9 2.6 2.0
15 4.54 5.3 8.6 9.1 8.8 7.9
30 5.87 6.8 14.3 16.4 14.5 12.4
45 7.13 8.6 21.0 28.7 21.4 19.0
60 10.81 10.1 29.4 37.3 32.7 28.7
90 16.19 15.2 45.0 50.4 46.1 39.6
120 19.99 21.0 57.8 66.1 54.8 52.9
Fig. 23
Table 12.  Dissolution of glimepiride solid dispersion (Physical mixture) with 
various carriers
Table 13 : DISSOLUTION OF GLIMEPIRIDE IN PURE FORM AND 
FROM SOLID DISPERSION  (SOLVENT EVAPORATION) WITH 
VARIOUS CARRIERS AT DRUG : CARRIER RATIO OF 1:2
MEDIUM :  0.2M Phosphate Buffer pH 7.4
TEMPERATURE : 37ºC±5ºC
RPM : 70
    
    Time (Min)
             
               Percentage Glimepiride dissolved
PURE DRUG 
(4 MG) SE (PEG 4000)
SE (HPMC)
0 0 0 0
5 1.36 5.2 2.1
10 2.03 7.5 3.20
15 4.54 15.1 10.0
30 5.87 28.3 19.4
45 7.13 40.5 30.2
60 10.81 52.4 39.5
90 16.19 63.7 52.4
120 19.99 76.57 69.3
Fig. 25
Table 14. DISSOLUTION OF GLIMEPIRIDE IN PURE FORM AND FROM 
SOLID DISPERSION  (FUSION METHOD) WITH VARIOUS 
CARRIERS AT DRUG : CARRIER RATIO OF 1:2
MEDIUM :  0.2M Phosphate Buffer pH 7.4
TEMPERATURE : 37ºC±5ºC
RPM : 70
    
    Time (Min)
             
               Percentage Glimepiride dissolved
PURE DRUG 
(4 MG) SE (PEG 4000)
SE (HPMC)
0 0 0 0
5 1.36 3.8 1.8
10 2.03 5.4 2.9
15 4.54 11.0 9.1
30 5.87 23.7 16.4
45 7.13 35.6 28.7
60 10.81 47.8 37.3
90 16.19 55.2 50.4
120 19.99 71.4 66.1
Fig. 26

Table 15.
DISSOLUTION OF GLIMEPIRIIDE IN PURE FORM ,PHYSICAL 
MIXTURE AND SOLVENT EVAPORATION  WITH PEG 4000  AT 
DRUG : CARRIER  RATIO OF 1:2
Time 
(min)
Percentage Glmepiride dissolved
Pure drug
(4mg)
PHYSICAL 
MIXTURE 
(1:1)
SE 
PEG 4000
( 1:2)
0 0 0 0
5 1.36 1.9 5.2
10 2.03 2.8 7.5
15 4.54 6.1 15.1
30 5.87 9.4 28.3
45 7.13 10.8 40.5
60 10.81 12.3 52.4
90 16.19 18.9 63.7
120 19.99 27.3 76.57
Fig. 27

Table 16 : Log percentage glimepiride un dissolved from pure form  and from 
PEG 4000  solid dispersions (solvent evaporation  method) of 1:2 ratio.
S.No Time (mins)
Percentage  Glimepiride  undissolved  from  solid 
dispersions (Log percentage Glimepiride undissolved)
Pure drug
Physical 
mixture (SE)PEG 4000
1 0 0 0
0
2 5 98.64(1.994)
98.10
(1.991)
94.8
(1.976)
3 10 97.97(1.991)
97.22
(1.987)
92.5
(1.966)
4 15 95.46(1.979)
93.91
(1.972)
84.90
(1.928)
5 30 94.13(1.973)
90.63
(1.957)
71.70
(1.855)
6 45 92.87(1.967)
89.22
(1.950)
59.5
(1.774)
7 60 89.19(1.950)
87.72
(1.942)
47.60
(1.677)
8 90 83.81(1.923)
81.12
(1.909)
36.3
(1.559)
9 120 80.01(1.903)
72.77
(1.861)
23.43
(1.369)
Fig. 28
Log percentage glimepiride un dissolved from pure form  and from PEG 4000  solid dispersions (solvent evaporation 
method) of 1:2 ratio.

Table 17: First order rate constant for glimepiride.
By Solvent evaporation method
Solid Dispersion K (min–1)
PURE DRUG 0.0010
PHYSICAL MIXTURE 0.0012
GLIIMEPIRIDE : PEG 4000 (SE)
1 : 2
0.0050
CHAPTER - 7
RESULTS AND DISCUSSION
Glimepiride is an effective anti diabetic which is practically insoluble 
in water, hence, dissolution is rate limiting. The present aim of this study is 
to  develop a  fast  release formulation  of  glimepiride  by solid  dispersion 
technology using different carrier, such as PEG4000 and HPMC.
• PREPRATION OF SOLIDDISPERSION
The solid dispersion of glimepiride were prepared by different techniques 
such as fusion method, solvent evaporation method and physical mixture 
method. The method of preparation for all  the three method were all ready 
mentioned in material and method. In all  methods the various drug and 
carrier ratios 1:1, 1:2, 1:3, and 1:4 had been used. The resultant produce 
were characterized by X-ray, DSC, in vitro dissolution studies.
• COMPATIBILITY STUDIES
FTIR Spectroscopy
Fourier transform infrared (FTIR) spectra of the samples were obtained in 
the  range  of  2000  to  400cm-1  using  JASCO  FTIR  410  Pc 
Spectrophotometer by using KBr disc method. The IR spectra of the solid 
dispersion  and  pure  samples  are  given  in  the  fig  –  to  fig-from the  IR 
spectra this study found that there were no incompatibility between drug 
and carrier such as PEG4000 and HPMC .
• CHARACTERIZATION
Powder X-ray diffraction 
The  fig  16  showed  a  numerous  distinctive  peaks  indicating  a  high 
crystallinity  of  pure  drug  of  glimepiride.  A solid  dispersion  containing 
glimepiride with HPMC   (fig 15) showed reduction intensive peaks. The X-
ray of solid dispersion  with PEG 4000  (fig 14) showed very less distinctive 
peaks.  That  indicates  confirmation  of  changing  the  nature  of  the 
compound from crystalline to amorphous nature. From this X-ray studies it 
conclude that PEG4000  is a best carriers for increasing solubility of poorly 
soluble glimepiride.
• DIFFERENTIAL SCANNING CALORIMETRY
The DSC of pure drug, polymer and all solid dispersion formulations were 
performed  using  Meffler  –  Teledo  DSC  831e  (Meffler   -  TeldoGmbh, 
Switzerland). From the DSC thermogram of glimepiride solid dispersion 
containing drug and PEG4000 the metting was found to be and 2150C  which 
is different from the pure drug( Metting point of glimepiride (2070 C )) from 
the  DSC thermo gram of  glimepiride  solid  dispersion  with  HPMC (1:2) 
which is prepared by solvent evaporation method was found to be 2000C 
which  shows  that  the  crystalline  nature  of  compound  getting  changed. 
From the  DSC studies  of  solid  dispersions  conclude  that  there  was  a 
change in nature of the compound. The DSC spectras are given in Fig 
17,18 & 19.
• INVITRO ANALYSIS:
The invitro dispersion studies of pure drug and all solid dispersion 
formulation with different ratios 1:1, 1:2, 1:3, and 1:4 by using two different 
carriers such as PEG  4000 and HPMC. The prepared solid dispersions of 
glimepiride  equivalent  to  4mg of  pure  drug  was  filled  in  hard  gelation 
capsule and dissolution studies were carried out in dissolution apparatus 
electro lab  TDT – 08L containing 900ml of PH 7.4 in at 37± 50c with rpm 
70.  The  samples  were  taken  at  different  interval  of  time.  Omin,  5min, 
10min, 15min, 30min, 45min, 60min, 90min and 120min. also absorbance 
were  recorded at  236nm.  From this  in  vitrostudies the solid  dispersion 
containing  drug  and  PEG4000 (1:2)  released  maximum  76.57%  W/V 
(Solvent evaporation method). The solid dispersion containing drug and 
HPMC (1:2) showed 69.3% (w/v) (solvent evaporation method). From this 
invitro studies it conclude that the solid dispersion containing glimepiride 
and PEG4000 (1:2) (Solvent  evaporation method) showed high release. The 
studies proved that one of the fast releasing dosage form for poorly water 
soluble glimepiride by using solid dispersion technology.
CHAPTER - 8
SUMMARY AND CONCLUSION
Studies were under taken on the preparation and evaluation of solid 
dispersion of glimepiride with a view to develop fast release formulation of 
glimepiride. In the prepration of solid dispersion carries such as PEG 4000 
and  HPMC  were  used.  In  this  present  study   solid  dispersions  were 
prepared by solvent evaporation and fusion methods.
The solid dispersions prepared were Interaction to be fine and free 
flowing powders. Interaction studies like IR spectra were shown and there 
was  no  interaction  between  drug  and  carriers  used.  All  the  solid 
dispersions prepared were found to be uniform in drug content.
X-ray  diffraction  studies  revealed  that  crystalline  nature  of 
glimepiride in pure form was reduced in the solid dispersions. This might 
be  the  reason  for  improved  dissolution,  it  was  also  indicates  the 
amorphous character of the solid dispersions, DSC thermo gram showed 
no interaction between drug and polymer and confirmed the amorphous 
nature of the solid dispersions.
Pure  drug  Good  correlation  was  observed  between  percentage 
carries  in  the  dispersions.  The  dissolution  of  glimepiride  from  all 
dispersions followed first order kinetics. Among the carriers used PEG4000 
gave the fastest dissolution rate and the order of dissolution of glimepiride 
from the various solid dispersions. Glimepiride solid dispersions in PEG4000 
prepared at drug: carrier  ratio of  1:2 was formulated in to capsule and 
evaluated  for  dissolution  characteristics.  The  dissolution  of  glimepiride 
capsule solid dispersions were found to be fast and rapid when compared 
to the pure drug formulation.
The solid dispersion containing drug: PEG4000 (1:2)  considered as a 
fast release dosage form of glimepiride when compared to pure drug and 
ration of glimepiride solid dispersions.
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